no | title  | author | date |
6.07.4.60/21 | Working materials Consultancy on Conversion planning for Mo-99 Production facilities from HEU to LEU | IAEA |
August 2010 |
6.07.4.60/23 | The Supply of Medical Radioisotopes. Implementation of the HLG-MR Policy Approach. Results from a Self-assessment by the Global 99Mo/99mTc Supply Chain | OECD, NEA |
March 2013 |
6.07.4.60/48 | The Supply of Medical Isotopes. An Economic Diagnosis and Possible Solutions | OECD, NEA |
2019 |
6.07.4.60/51 | Study on sustainable and resilient supply of medical radioisotopes in the EU. Therapeutic Radionuclides | Joint Research Centre, Ligtvoet, Scholten, Davé, King, Petrosova, Chiti, Goulart De Medeiros, Joerger |
September 2021 |
6.07.4.60/09 | Stralingsbelasting van leden van de bevolking als gevolg van medische toepassing van radiofarmaca: consequenties voor ontslagcriteria | H.Beekhuis, Min. VROM |
May 1992 |
6.07.4.60/22 | Straling in ziekenhuizen | AbvaKabo |
|
6.07.4.60/28 | Ruwe schets van de problemen voor de behandeling van Nederlandse patiënten bij een plotselinge productiestop van medische isotopen in Nederland | RIVM, Smetsers, Bijwaard, Roobol |
July 2016 |
6.07.4.60/18 | Report on Molybdenum 99 production for nuclear medicine 2010-2020 | AIPES |
November 2008 |
6.07.4.60/19 | Radioisotopes in Medicine | E.W.Phelan, AEC |
1966 |
6.07.4.60/20 | Radioisotopes and life processes | W.Kosieleski, R.Baserga |
1967 |
6.07.4.60/17 | Radio-isotopen (IBA Bedrijfsfolder) | IBA |
1999 |
6.07.4.60/34 | Radio-activiteit in dienst van de arts | AO-reeks, T.van Leeuwen |
November 1976 |
6.07.4.60/01 | Radiation and medicine | UKAEA |
June 1992 |
6.07.4.60/39 | Production Of 99Tc On A Medical Cyclotron: A Feasibility Study | J.E.Beaver. H.B.Hupf |
November 1971 |
6.07.4.60/30 | Productie en gebruik van medische radio-isotopen
in Nederland - Huidige situatie en toekomstverkenning | RIVM, Roobol, van der Reijden, de Waard–Schalk, Bijwaard |
July 2017 |
6.07.4.60/52 | Opportunities and Approaches for Supplying Molybdenum-99 and Associated Medical Isotopes to Global Markets
| National Academy |
2018 |
6.07.4.60/47 | Nuclear Medicine's Double Hazard. Imperiled Treatment and the Risk of Terrorism | C.Hansell |
July 2008 |
6.07.4.60/24 | Nuclear Medicine without Nuclear Reactors or Uranium Enrichment | AAAS, Updegraff, Hoedl |
May 2013 |
6.07.4.60/27 | Molybdenum-99 for Medical Imaging | National Academies of Sciences |
September 2016 |
6.07.4.60/13 | Medische stralingsbelasting in de nucleaire geneeskunde | B.Hessen |
1982 |
6.07.4.60/33 | Medische isotopen. Belang voor de wereld en kansen voor Nederland | Nucleair Nederland |
April 2017 |
6.07.4.60/04 | Medical Valley. Nucleaire geneeskunde in de Pettense duinen | ECN, Mallinckrodt Medical |
|
6.07.4.60/37 | Medical isotopes. Global importance and opportunities for the Netherlands in a European context
| Nucleair Nederland |
November 2017 |
6.07.4.60/55 | Medical isotope production using local cyclotrons - A comparative study between Denmark and the Netherlands
| Technopolis group |
January 2022 |
6.07.4.60/40 | Medical isotope production using Lighthouse accelerator | J.W.Blokker |
November 2017 |
6.07.4.60/16 | Medical Imaging. A discussion paper | A.Sinclair, Medical Devices |
March 1998 |
6.07.4.60/44 | Maximum reasonable radioxenon releases from medical isotope production facilities and their effect on monitoring nuclear explosions | Th.W.Bowyer, R.kephart, P.W.Eslinger, J.Friese |
September 2012 |
6.07.4.60/41 | Marktontwikkeling en leveringszekerheid voor medische radionucliden
| Roobol, de Waard, RIVM |
July 2019 |
6.07.4.60/38 | Marktontwikkeling en leveringszekerheid voor medische isotopen | Roobol, de Waard, RIVM |
April 2018 |
6.07.4.60/42 | Marktontwikkeling en leveringszekerheid
voor medische radionucliden, aanvulling | Roobol, de Waard, RIVM |
September 2019 |